About the job
ABOUT EVIDENCE ACTION
At Evidence Action, we implement data-driven interventions that transform lives on an unprecedented scale. We identify neglected global health challenges and deploy proven solutions to build a healthier future for generations to come.
Our model translates cutting-edge academic research (including that of Nobel Prize-winning economists) into actionable strategies. We meticulously measure progress and outcomes at every stage to ensure we make a real impact on those living in poverty who suffer from preventable or treatable health issues. Present in nine countries, our team of over 900 individuals has reached more than 500 million people and collaborates closely with governments to scale these interventions.
- Our Deworm the World program has delivered over 2 billion treatments, significantly reducing worm prevalence and generating more than $23 billion in lifetime productivity gains.
- Through Safe Water Now, we have saved the lives of over 15,000 children.
- Our Accelerator program explores untapped opportunities in global health by testing low-cost interventions with the greatest potential to save and improve lives.
PROGRAM CONTEXT
One of Evidence Action's initiatives is the 'Syphilis-Free Start' program, which partners with health ministries to enhance screening and treatment of syphilis in pregnant women, aiming to prevent mother-to-child transmission of this disease. By leveraging investments in HIV/AIDS efforts, our goal is to address screening gaps in syphilis by introducing or expanding dual testing for HIV and syphilis and to overcome treatment barriers for pregnant women testing positive for syphilis.
The SFS program was first launched in Liberia in 2020. Our efforts in Liberia (in partnership with the Ministry of Health) increased syphilis screening from 7% to 88% in three and a half years, with 94% of pregnant women testing positive for syphilis receiving treatment. Within a year of receiving technical assistance, the Liberian Ministry of Health covered national needs for dual testing and benzathine penicillin through the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM). Since then, we have expanded this program to Zambia, Cameroon, and most recently, Côte d'Ivoire.

